Claims for Patent: 8,759,093

Summary for Patent: 8,759,093

Title:	Method for determining the selectivity of a pre-synaptic neuromuscular blocking substance
Abstract:	The present invention relates to a method for determining the selectivity of a pre-synaptic neuromuscular blocking substance for striated muscle or smooth muscle. The method comprises measuring the effect induced by a pre-determined quantity of pre-synaptic neuromuscular blocking substance upon electrically stimulating striated muscle tissue, measuring the effect induced by a pre-determined quantity of a pre-synaptic neuromuscular blocking substance upon electrically stimulating smooth muscle tissue, and calculating a quotient of the results obtained in order to determine the selectivity of the pre-synaptic neuromuscular blocking substance for striated muscle or for smooth muscle.
Inventor(s):	France; Richard (Nottingham, GB), Quirk; Robin (Nottingham, GB), Riccalton-Banks; Lisa (Nottingham, GB), Pickett; Andrew Martin (Berkshire, GB)
Assignee:	Ipsen Developments Limited (Berkshire, GB)
Application Number:	11/659,445
Patent Claims:	1. A method for determining the selectivity of a pre-synaptic neuromuscular blocking substance comprising the following steps: (a) determining the minimum voltage V.sub.mst needed to induce the contraction of a striated muscle tissue, said striated muscle tissue being connected to an electrical stimulator through a motor nerve; (b) adding to the system of step (a) a pre-determined quantity of a pre-synaptic neuromuscular blocking substance; (c) electrically stimulating, at a voltage at least equal to V.sub.mst, the muscle tissue by train pulse stimulation, thereby extending life span of the muscle tissue and carrying out the stimulation over a period of at least 1 hour to increase the sensitivity of the method; (d) measuring the effect induced by the pre-determined quantity of a pre-synaptic neuromuscular blocking substance on the striated muscle tissue, said effect being selected from (i) time to paralysis of said striated muscle tissue, (ii) variation in the contraction rate of said striated muscle tissue, (iii) variation in the contraction distance of said striated muscle tissue, (iv) variation in the force of contraction of said striated muscle tissue, and (v) variation in the end plate potential or the miniature end plate potential of said striated muscle tissue; (e) determining the minimum voltage V.sub.msm needed to induce the contraction of a smooth muscle tissue, said smooth muscle tissue being linked to an electrical stimulator through an electrically conducting liquid; (f) adding to the system of step (e) the same pre-determined quantity of the same pre-synaptic neuromuscular blocking substance as for step (b); (g) electrically stimulating, at a voltage at least equal to V.sub.msm, the muscle tissue by train pulse stimulation, thereby extending life span of the muscle tissue and carrying out the stimulation over a period of at least 1 hour to increase the sensitivity of the method; (h) measuring the effect induced by said pre-determined quantity of the pre-synaptic neuromuscular blocking substance on the smooth muscle tissue, said effect being selected from (i) time to paralysis of said smooth muscle tissue, (ii) variation in the contraction rate of said smooth muscle tissue, (iii) variation in the contraction distance of said smooth muscle tissue, (iv) variation in the force of contraction of the smooth muscle tissue, and (v) variation in the end plate potential or the miniature end plate potential of said smooth muscle tissue; and (i) calculating the quotient of the result obtained in step (h) by the result obtained in step (d), wherein, the higher above 1 said quotient is, the more selective for smooth muscle the pre-synaptic neuromuscular blocking substance is; or, conversely, calculating the quotient of the result obtained after step (d) by the result obtained after step (h), wherein, the higher above 1 said quotient is, the more selective for striated muscle the pre-synaptic neuromuscular blocking substance is. 2. The method of claim 1, wherein said striated muscle tissue and said smooth muscle tissue are derived from the same animal species. 3. The method of claim 1, wherein said muscle tissue is immersed in a buffer. 4. The method of claim 3, wherein said buffer is a physiological buffer. 5. The method of claim 3, wherein said buffer comprises an energy source. 6. The method of claim 5, wherein said energy source is an ATP energy source. 7. The method according to claim 3, wherein said buffer is oxygenated. 8. The method according to claim 7, wherein said buffer is an oxygenated physiological buffer containing glucose. 9. The method of claim 1, wherein said pre-synaptic neuromuscular blocking substance is a botulinum toxin. 10. The method of claim 9, wherein said botulinum toxin is selected from botulinum toxin type A, botulinum toxin type B and botulinum toxin type F. 11. The method of claim 9, wherein said botulinum toxin is selected from botulinum toxin type A and botulinum toxin type B. 12. The method of claim 11, wherein said botulinum toxin is botulinum toxin type A. 13. The method of claim 1, wherein said pre-synaptic neuromuscular blocking substance is a bungarotoxin. 14. The method of claim 13, in which the bungarotoxin is .alpha.-bungarotoxin.

Details for Patent 8,759,093

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2024-08-04